AGTR1 and kidney cancer: These include inflammation, renal bloodflow (RBF), overexpression of angiotensin II type 1 receptors (AT1R),mitochondrial complex I (MC-I) activity, and kidney cancer. As a result, recent years have seen increasedefforts to develop novel PET radiopharmaceuticals for the assessmentof kidney function.